Think of Xultophy as Similar to Soliqua for Type 2 Diabetes

June 2017

You'll see the new injectable, Xultophy, for type 2 diabetes.

Xultophy (ZUL-toh-fye) combines the long-acting "basal" insulin, Tresiba (insulin degludec) and the GLP-1 agonist, Victoza (liraglutide).

Think of Xultophy as similar to Soliqua, which is a combo of Lantus (insulin glargine) and Adlyxin (lixisenatide).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Vaccines Use Simple Strategies to Identify Patients Who May Need Vaccines
Diabetes Meds Think of Xultophy as Similar to Soliqua for Type 2 Diabetes
Practice Ensure Labels Are Easy to Read for Visually Impaired Patients
Ear Health Expect Kids With Ear Tubes to Get Otic Antibiotics Instead of Oral Antibiotics
NSAIDs Watch for Ketorolac Rxs Lasting Longer Than 5 Days
Anticoagulants Expedite Prior Auths for Lower Doses of Eliquis and Xarelto
Opioids Stay Alert for Codeine or Tramadol Rxs for Kids and Breastfeeding Women
Geriatrics Watch for Dementia Patients Taking Antipsychotics Long-Term
Migraine Understand How Therapies for Menstrual Migraine Compare
PPIs Try to Find Out Why Patients Are Getting a PPI
Fibromyalgia Be Familiar With Meds for Fibromyalgia